Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.53 is 65% above its 5-year average of -1.49, near the high end of its 5-year range (-2.76–-0.53).
44.21% above its 12-month average of -0.95.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.20.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 22 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.53
EARNINGS PER SHARE (EPS) AVG TTM
-0.95
EARNINGS PER SHARE (EPS) AVG 3Y
-1.58
EARNINGS PER SHARE (EPS) AVG 5Y
-1.49
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+44.21%
CURRENT VS 3Y AVG
+66.56%
CURRENT VS 5Y AVG
+64.51%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Tenaya Therapeutics, Inc.
Market Cap
$118.59M
Earnings Per Share (EPS)
-0.53
TTM Avg
-0.95
3Y Avg
-1.58
5Y Avg
-1.49
Market Cap
$118.83M
Earnings Per Share (EPS)
-4.09
TTM Avg
-2.59
3Y Avg
-6.03
5Y Avg
-6.97
Market Cap
$117.76M
Earnings Per Share (EPS)
-40.87
TTM Avg
-73.79
3Y Avg
-78.14
5Y Avg
-71.60
Market Cap
$119.84M
Earnings Per Share (EPS)
-1.65
TTM Avg
-6.80
3Y Avg
-14.48
5Y Avg
-27.17
Market Cap
$120.41M
Earnings Per Share (EPS)
-1.22
TTM Avg
-1.33
3Y Avg
-1.36
5Y Avg
-1.18
Market Cap
$116.76M
Earnings Per Share (EPS)
-0.33
TTM Avg
-0.41
3Y Avg
-0.34
5Y Avg
-0.29
Market Cap
$120.58M
Earnings Per Share (EPS)
-0.28
TTM Avg
-1.88
3Y Avg
-2.46
5Y Avg
-1.80
Market Cap
$115.67M
Earnings Per Share (EPS)
-0.99
TTM Avg
-1.38
3Y Avg
-1.93
5Y Avg
-2.07
Market Cap
$122.43M
Earnings Per Share (EPS)
N/A
TTM Avg
-5.70
3Y Avg
-9.83
5Y Avg
-0.70
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tenaya Therapeutics, Inc. (TNYA) | $118.59M | -0.53 | -0.95 | -1.58 | -1.49 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.83M | -4.09 | -2.59 | -6.03 | -6.97 |
| Spruce Biosciences, Inc. (SPRB)vs › | $117.76M | -40.87 | -73.79 | -78.14 | -71.60 |
| Cibus, Inc. (CBUS)vs › | $119.84M | -1.65 | -6.80 | -14.48 | -27.17 |
| Seer, Inc. (SEER)vs › | $120.41M | -1.22 | -1.33 | -1.36 | -1.18 |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | -0.33 | -0.41 | -0.34 | -0.29 |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | -0.28 | -1.88 | -2.46 | -1.80 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | -0.99 | -1.38 | -1.93 | -2.07 |
| BGM Group Ltd. (BGM)vs › | $122.43M | N/A | -5.70 | -9.83 | -0.70 |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $122.66M | -13.24 | -14.57 | -14.57 | -81991.29 |
Trailing EPS (TTM)
$-0.53
Forward EPS (Est.)
$-0.48
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.59 |
| 2024-12-31 | -1.31 |
| 2023-12-31 | -1.68 |
| 2022-12-31 | -2.76 |
| 2021-12-31 | -1.69 |
| 2020-12-31 | -0.93 |
| 2019-12-31 | -0.95 |
